GR3019460T3 - Infective drug delivery system - Google Patents

Infective drug delivery system

Info

Publication number
GR3019460T3
GR3019460T3 GR960400835T GR960400835T GR3019460T3 GR 3019460 T3 GR3019460 T3 GR 3019460T3 GR 960400835 T GR960400835 T GR 960400835T GR 960400835 T GR960400835 T GR 960400835T GR 3019460 T3 GR3019460 T3 GR 3019460T3
Authority
GR
Greece
Prior art keywords
drug delivery
delivery system
infective drug
retrovirus
serve
Prior art date
Application number
GR960400835T
Other languages
English (en)
Inventor
Francis P Mccormick
Michael Kriegler
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Publication of GR3019460T3 publication Critical patent/GR3019460T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GR960400835T 1986-04-24 1996-03-29 Infective drug delivery system GR3019460T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85586586A 1986-04-24 1986-04-24

Publications (1)

Publication Number Publication Date
GR3019460T3 true GR3019460T3 (en) 1996-06-30

Family

ID=25322287

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960400835T GR3019460T3 (en) 1986-04-24 1996-03-29 Infective drug delivery system

Country Status (9)

Country Link
US (2) US5652130A (el)
EP (1) EP0243204B1 (el)
JP (2) JP2773833B2 (el)
AT (1) ATE133449T1 (el)
CA (1) CA1310924C (el)
DE (1) DE3751682T2 (el)
ES (1) ES2083353T3 (el)
GR (1) GR3019460T3 (el)
HK (1) HK38497A (el)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
DE3990262T1 (de) * 1988-03-21 1991-04-04 Viagene Inc Rekombinante retroviren
AU651311B2 (en) * 1988-03-21 1994-07-21 Chiron Corporation Recombinant retroviruses
EP0832980B1 (en) * 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
EP0466815A4 (en) * 1989-04-05 1992-09-02 Novacell Corpporation Infectious targetted replication-defective virion
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
EP0497922B1 (en) * 1989-10-24 2002-01-30 Chiron Corporation Infective protein delivery system
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
ATE142266T1 (de) * 1989-12-21 1996-09-15 Whitehead Biomedical Inst Verfahren zum transport von molekülen in eukaryotenzellen
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
JP3547129B2 (ja) * 1991-02-19 2004-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変更宿主域を有するウィルス粒子
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
ATE152915T1 (de) * 1991-11-29 1997-05-15 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
EP0729511A1 (en) 1993-11-18 1996-09-04 Chiron Corporation Compositions and methods for utilizing conditionally lethal genes
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
CA2211743A1 (en) * 1995-02-21 1996-08-29 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
AU708273B2 (en) * 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
US6136598A (en) * 1997-05-09 2000-10-24 Fred Hutchinson Cancer Research Center Mus dunni endogenous retroviral packaging cell lines
AU7486898A (en) 1997-05-13 1998-12-08 Stuart D Edwards Global medical treatment method and apparatus
US5973119A (en) 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
ES2151403B1 (es) * 1998-07-13 2001-07-01 Hernandez Bronchud Miguel Linea celular transformada de rata productora de tnf-alfa humano recombinante.
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
KR100630880B1 (ko) * 1999-12-31 2006-10-02 엘지.필립스 엘시디 주식회사 엑스레이 영상 감지소자 및 그 제조방법
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
DE60137223D1 (de) 2000-06-28 2009-02-12 Amgen Inc Thymus-stroma lymphopoietin rezeptor-moleküle und deren verwendung
US20030031628A1 (en) * 2001-07-09 2003-02-13 Ming Zhao Imaging infection using fluorescent protein as a marker
US20040025194A1 (en) * 2002-02-22 2004-02-05 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003298816C1 (en) 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
EP1758999B1 (en) 2004-06-22 2011-03-09 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
WO2006086607A2 (en) * 2005-02-10 2006-08-17 Emory University Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation
WO2009018250A2 (en) * 2007-07-30 2009-02-05 University Of Iowa Research Foundation Use of rpa4 and rpa4/rpa32 hybrid polypeptides for modulating cell proliferation
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
EP3248610B1 (en) 2009-05-05 2023-12-20 Amgen Inc. Fgf21 mutants and uses thereof
CA2764835A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
AU2010326024A1 (en) * 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
WO2011146938A1 (en) 2010-05-21 2011-11-24 NanoOncology, Inc. Reagents and methods for treating cancer
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS605692Y2 (ja) * 1977-06-02 1985-02-22 日本電気株式会社 宅内機器構造
JPS61922Y2 (el) * 1979-12-17 1986-01-13
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
US4663281A (en) * 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
WO1985005629A1 (en) * 1984-05-25 1985-12-19 Dana-Farber Cancer Institute Ltr vectors, methods of preparation and use
WO1985005618A1 (en) * 1984-06-06 1985-12-19 Takeda Chemical Industries, Ltd. Process for preparing interferon derivative
EP0192658A4 (en) * 1984-07-30 1987-07-13 Salk Inst For Biological Studi RETROVIRAL GENE TRANSFER VECTORS.
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2571737B1 (fr) * 1984-10-15 1987-02-20 Agronomique Inst Nat Rech Vecteurs de clonage ou d'expression comportant le genome du virus de l'erythroblastose aviaire et cellules transfectees par ces vecteurs
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
US4839284A (en) * 1985-05-16 1989-06-13 New York University Murine host-vector system capable of amplifying and expressing transfected genes
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
WO1989007150A1 (en) * 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same

Also Published As

Publication number Publication date
US5652130A (en) 1997-07-29
EP0243204A2 (en) 1987-10-28
HK38497A (en) 1997-04-04
DE3751682T2 (de) 1996-09-12
DE3751682D1 (de) 1996-03-07
EP0243204A3 (en) 1989-02-22
JP2843318B2 (ja) 1999-01-06
ATE133449T1 (de) 1996-02-15
ES2083353T3 (es) 1996-04-16
CA1310924C (en) 1992-12-01
JPH10287590A (ja) 1998-10-27
JPS63157985A (ja) 1988-06-30
US5635399A (en) 1997-06-03
JP2773833B2 (ja) 1998-07-09
EP0243204B1 (en) 1996-01-24

Similar Documents

Publication Publication Date Title
GR3019460T3 (en) Infective drug delivery system
IT1232243B (it) Composizioni farmaceutiche a base di ciclosporine
DE3586206D1 (de) Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung.
ZA852160B (en) Storage-stable,quick-disintegrating pressed shapes containing pharmaceutical active substances
IL90058A0 (en) Hiv envelope peptide,vaccines containing it,monoclonal antibodies directed against said peptide and pharmaceutical compositions containing said antibodies
IL81950A0 (en) 2-azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof processes for the preparation thereof and pharmaceutical compositions containing them
FI891774A0 (fi) Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi
IL85885A0 (en) Cyclic peptides,their preparation and pharmaceutical compositions containing them
WO1991015512A3 (en) Hiv envelope polypeptides
TW290455B (el)
WO1993018055A3 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
AU1226288A (en) Processes for the preparation of medicinal compositions, compositions obtained by these processes and use thereof for the preparation of medicines against viral hepatitis b and acquired immunodeficiency syndrome
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
DE3874610D1 (el)
NO180636C (no) Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1
DE68902300D1 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
DE3068074D1 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
EP0030848A3 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
AU2520692A (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus
DE3067790D1 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
AU7071487A (en) Chlorpheniramine therapy
IL85651A0 (en) Optically active oxo-isoindolinyl derivatives,their preparation and pharmaceutical compositions containing them
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions
AU632039C (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0264017A3 (en) Pharmaceutical compositions having healing activity